Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Lyme Disease

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Lyme Disease in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baranton, G; Fujii, N; Ishii, N; Isogai, E; Isogai, H; Kimura, K; Nishikawa, T; Postic, D1
Isogai, E; Isogai, H; Kimura, K1

Reviews

1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Lyme Disease

ArticleYear
[Platelet activating factor (PAF) and Lyme disease].
    Nihon saikingaku zasshi. Japanese journal of bacteriology, 1996, Volume: 51, Issue:3

    Topics: Animals; Borrelia burgdorferi Group; Cell Communication; Cytokines; Endothelium, Vascular; Humans; Lyme Disease; Neutrophils; Platelet Activating Factor; Platelet Activation; Skin; Spirochaetales

1996

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Lyme Disease

ArticleYear
Platelet-activating-factor-mediated pathogenesis in Lyme disease.
    Infection and immunity, 1996, Volume: 64, Issue:3

    Topics: Animals; Lyme Disease; Male; Mice; Mice, Inbred C3H; Neutrophils; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors

1996